Summary
RDDA Chart
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division Aman Vij - Unidentified Company Amey Chalke - JM Financial Institutional Securities Limited, Research Division Bino Joseph Pathiparampil - Elara Securities (India) Private Limited, Research Division Damayanti Kerai - HSBC Global Investment Research Foram Prashant Parekh - BOB Capital Markets Limited, Research Division Harith Mohammed Ahamed - Spark Institutional Equities Private Limited, Research Division Kunal Dhamesha - Macquarie Research Madhav Marda - Unidentified Company Fidelity Investments - Unidentified Company Neha Manpuria - BofA Securities, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Shashank Krishnakumar - Emkay Global Financial Services Ltd.
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.
Dr. Reddy's Laboratories Ltd. Dividends
 RDY In 11 months Estimated | Annual | $0.09 Per Share |
| RDY 2 weeks ago Paid | Annual | $0.09 Per Share |
| RDY 30 Jul 2024 Paid | Annual | $0.1 Per Share |
| RDY 15 Jul 2024 | Annual | $0.48 Per Share |
| RDY 28 Jul 2023 Paid | Annual | $0.1 Per Share |
| RDY 7 Jul 2023 | Annual | $0.1 Per Share |
Dr. Reddy's Laboratories Ltd. Earnings
| 4 Nov 2025 (In 2 months) Date | | 0.18 Cons. EPS | - EPS |
| 24 Oct 2025 (In 2 months) Date | | 0.23 Cons. EPS | - EPS |
| 23 Jul 2025 Date | | 0.21 Cons. EPS | 0.2 EPS |
| 28 Jan 2025 Date | | 16.15 Cons. EPS | 16.94 EPS |
| 25 Oct 2024 Date | | 0.98 Cons. EPS | 0.18 EPS |
| RDY In 11 months Estimated | Annual | $0.09 Per Share |
| RDY 2 weeks ago Paid | Annual | $0.09 Per Share |
| RDY 30 Jul 2024 Paid | Annual | $0.1 Per Share |
| RDY 15 Jul 2024 | Annual | $0.48 Per Share |
| RDY 28 Jul 2023 Paid | Annual | $0.1 Per Share |
| RDY 7 Jul 2023 | Annual | $0.1 Per Share |
| 4 Nov 2025 (In 2 months) Date | | 0.18 Cons. EPS | - EPS |
| 24 Oct 2025 (In 2 months) Date | | 0.23 Cons. EPS | - EPS |
| 23 Jul 2025 Date | | 0.21 Cons. EPS | 0.2 EPS |
| 28 Jan 2025 Date | | 16.15 Cons. EPS | 16.94 EPS |
| 25 Oct 2024 Date | | 0.98 Cons. EPS | 0.18 EPS |
Dr. Reddy's Laboratories Ltd. (RDDA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Dr. Reddy's Laboratories Ltd. ever had a stock split?
Dr. Reddy's Laboratories Ltd. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Erez Israeli CEO | XDUS Exchange | US2561352038 ISIN |
| IN Country | 27,048 Employees | 25 Jul 2025 Last Dividend | 7 Sep 2006 Last Split | 11 Apr 2001 IPO Date |
Overview
Dr. Reddy's Laboratories Limited represents a multifaceted pharmaceutical entity with a global footprint, engaging in an integrated range of pharmaceutical activities. Established in 1984 and based in Hyderabad, India, the company maintains a broad operation spectrum through its distinct segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. These segments underline the company's diversified approach, encompassing the production and marketing of generic and branded pharmaceutical products, active pharmaceutical ingredients (APIs), and contract research services, along with a focused effort on developing therapies in oncology and inflammation. Their commitment to innovation and quality places them among the leading pharmaceutical companies worldwide.
Products and Services
- Global Generics
This segment is pivotal in manufacturing and marketing prescription and over-the-counter pharmaceutical products, available both under brand names and as generic formulations equivalent to branded counterparts. Dr. Reddy’s has made significant strides in the biologics domain under this segment, indicating a strong emphasis on advancing therapeutic solutions and accessibility.
- Pharmaceutical Services and Active Ingredients (PSAI)
A crucial arm of Dr. Reddy’s, the PSAI segment is responsible for the manufacturing and marketing of active pharmaceutical ingredients and intermediates – the essential components for finishing pharmaceutical products. Notably, it extends contract research services, catering to the diverse requirements of customers by providing custom synthesized APIs and steroids. This segment underscores the company’s role as a vital player in the pharmaceutical value chain, bolstering the global supply of key pharmaceutical ingredients.
- Others
Under this segment, Dr. Reddy's delineates its focus on the research and development department, particularly in crafting therapies for oncology and inflammation. Additionally, it embarks on the development of differentiated formulations aimed at enhancing therapeutic efficacy and patient compliance. Another noteworthy area within this segment is their investment in digital healthcare solutions and IT-enabled business support services, demonstrating a forward-looking approach to adapting in an increasingly digitalized healthcare landscape.
Contact Information
